Regenerative Therapies Market Size, Trends, Shares, Insights and Forecast - 2027

SEATTLE - Sept. 9, 2020 - PRLog -- The global Regenerative Therapies Market is estimated to account for US$ 10,421.5 Mn in terms of value in 2019 and is expected to reach US$ 45,940.7 Mn by the end of 2027.

Increasing prevalence of neurological disorders is expected to offer lucrative growth opportunities for players in the market. For instance, according to the study, "Prevalence of Parkinson's disease (PD) across North America", published in July 2018 in the journal Nature, the number of people suffering from PD is expected to reach 930,000 in 2020 and 1,238,000 in 2030.

Global Regenerative Therapies Market: Restraints

Lack of financial-backing of smaller firms is expected to hinder growth of the global regenerative therapies market. A common trait in the regenerative therapies industry is the unavailability of proper financing options for smaller organizations. This is one of the main factors hampering R&D in the field of regenerative therapies. Quite observed in resource-poor settings, many promising targets have been abandoned half way during clinical trial phase due to lack of financing support stemming from insufficient data on proven efficacy.

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/regenerative-therapies-market-3712

Orthopedic segment held dominant position in the global regenerative therapies market in 2019, accounting for 37.2% share in terms of value, followed by soft tissue repair, and cardiovascular, respectively. Rampant research activities and rapid development of innovative products by key players is expected to support growth of the segment.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/3712

Market Trends

The translational pipeline from basic research to the delivery of innovative stem cell-based therapies is covered by a variety of European legal instruments,  ranging from regulations on marketing authorization (Regulation (EC) no. 1394/2007) to Directives about clinical trials (Directive 2001/20/EC) and guidelines of good clinical practice (Directive 2001/83/EC, Directive 2009/120/EC).

Global Regenerative Therapies Market: Competitive Landscape

March 2020: BioStem Life Sciences received its ISBT 128 Registration from the International Council for Commonality in Blood Banking Automation

February 2019: Pluristem Therapeutics Inc. collaborated with NASA's Ames Research Center to evaluate the potential of its PLX cell therapies in preventing and treating medical conditions caused during space missions

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/3712